Skip to main content
Premium Trial:

Request an Annual Quote

Genome Therapeutics, ArQule to Collaborate on Genomic Drug Discovery

Premium

MEDFORD, Mass.--ArQule here and Genome Therapeutics of Waltham, Mass., announced they will collaborate to discover novel drugs to combat bacterial and fungal diseases. ArQule will screen its proprietary chemical libraries against Genome Therapeutics' bacterial and fungal disease targets to identify and optimize small molecule antiinfectives.

Under terms of the agreement, ArQule will use validated bacterial and fungal targets from Genome Therapeutics' proprietary PathoGenome database to identify compounds with biological activity from ArQule's mapping array program. Once active leads are identified, the collaborators intend to use ArQule's directed array program to rapidly optimize lead compounds. ArQule and Genome Therapeutics will share ownership rights to any active lead compounds and will share any revenues upon commercialization of those compounds.

"We are collaborating with ArQule so that we can generate high-quality IND candidates as quickly as possible," said Robert Hennessey, Genome Therapeutics CEO. "ArQule's diverse pure compound libraries and advanced screening capabilities will help us to identify promising new drugs to fight bacterial and fungal infections. Opportunities for new anti-infectives are large and growing, spurred by the increasing problem of microbial resistance to existing classes of drugs."

ArQule CEO Eric Gordon said, "By applying ArQule's chemistry capability, Genome Therapeutics has a tremendous opportunity to speed its discovery programs, and ArQule has an opportunity to participate in the discovery and development of a portfolio of new products."

Filed under

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.